0001144204-18-012636.txt : 20180302 0001144204-18-012636.hdr.sgml : 20180302 20180302184415 ACCESSION NUMBER: 0001144204-18-012636 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180228 FILED AS OF DATE: 20180302 DATE AS OF CHANGE: 20180302 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Capponi Vincent CENTRAL INDEX KEY: 0001368151 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36792 FILM NUMBER: 18663961 MAIL ADDRESS: STREET 1: MEDASORB TECHNOLOGIES STREET 2: 7 DEER PARK DRIVE, SUITE K CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cytosorbents Corp CENTRAL INDEX KEY: 0001175151 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 980373793 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7 DEER PARK DRIVE, SUITE K CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 BUSINESS PHONE: 973-329-8885 MAIL ADDRESS: STREET 1: 7 DEER PARK DRIVE, SUITE K CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 FORMER COMPANY: FORMER CONFORMED NAME: MedaSorb Technologies CORP DATE OF NAME CHANGE: 20060807 FORMER COMPANY: FORMER CONFORMED NAME: GILDER ENTERPRISES INC DATE OF NAME CHANGE: 20020611 4 1 tv487685_form4.xml FORM 4 X0306 4 2018-02-28 0 0001175151 Cytosorbents Corp CTSO 0001368151 Capponi Vincent C/O CYTOSORBENTS CORPORATION 7 DEER PARK DRIVE, SUITE K MONMOUTH JUNCTION NJ 08852 0 1 0 0 Chief Operating Officer Common Stock 2018-02-28 4 A 0 38000 0 A 307451 D Stock Option (right to buy) 5.60 2018-02-28 4 A 0 89250 0 A 2027-02-24 Common Stock 89250 89250 D On February 24, 2017, the reporting person was granted an option to purchase 105,000 shares of Common Stock pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"), which was to vest upon achievement of certain performance goals as determined in the discretion of the Compensation Committee of the Board of Directors of CytoSorbents Corporation (the "Company"). This grant was reported on a Form 4 filed on February 28, 2017. On February 28, 2018, the Compensation Committee of the Board of Directors of the Company determined that 85% of such performance criteria was achieved during 2017, resulting in vesting of 89,250 shares underlying this option. These shares represent restricted stock units which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the Plan: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016 and (c) 125,000 RSUs granted on April 8, 2015, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 11,980 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof , (b) 7,667 of the RSUs granted on June 7, 2016 and unvested as of the date hereof and (c) 38,000 RSUs granted on February 28, 2018 and reported on this Form 4 and (iii) 52,904 shares of common stock owned by the reporting person. /s/ Vincent Capponi 2018-03-02